Sixty-One Years of Pancreatic Cancer in Denmark From 1943 to 2003

Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark.
Pancreas (Impact Factor: 2.96). 04/2009; 38(4):374-8. DOI: 10.1097/MPA.0b013e31819b71ae
Source: PubMed


We report the incidence rates of pancreatic cancer in Denmark during 61 years of data registration, from 1943 to 2003.
On the basis of reports in the nationwide, population-based Danish Cancer Registry, we calculated age-standardized, period-specific incidence rates of pancreatic cancer.
A total of 32,654 incident cases of pancreatic cancer were evaluated (male-female ratio, 1.4). The age-standardized incidence rate of pancreatic cancer increased steadily in the beginning of the study period from 3.75/100,000 person-years in 1943 to 1947 to the maximum of 9.96/100,000 person-years in 1968 to 1972 among men and from 2.95 in 1943 to 1947 to the maximum of 7.04 in 1978 to 1982 among women. The incidence rates declined between 1968 to 1972 and 1988 to 1992 for men and between 1978 to 1982 and 2003 for women. Most tumors were located in the exocrine pancreas, and most were adenocarcinomas. More than 40% were located in the head of the pancreas; 14% were localized, 21% were regionally spread, and 36% were metastatic at the time of diagnosis. During the period 1978 to 2003, the percentages of histologically or cytologically verified adenocarcinomas remained relatively steady, approximately 30%.
The incidence rate of pancreatic cancer increased at the beginning of the 61 years of registration and declined slightly thereafter.

5 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pancreatic cancer is the second most frequent gastrointestinal cancer in the Western world. Few reports on concomitant trends in pancreatic cancer incidence, diagnosis, mortality and survival exist at the national level. This study provides a baseline overview of the temporal patterns in these four indicators over the past four decades in Norway. We analysed trends in incidence, basis of diagnosis, relative survival and mortality from the Cancer Registry of Norway for the period 1965-2007. Included were 21,663 patients with pancreatic cancers. Incidence and mortality rates remained at around 6-8 per 100,000 over the study period. Diagnoses based on clinical examination alone dropped from 12.5% (in the 1950s) to <1% (in the 2000s), while use of imaging techniques, such as CT and MRI, increased from 3.6% to >30%. Previously high rates of autopsy-verified diagnosis and non-therapeutic surgery decreased accordingly. Consistently more primary tumours (from 12.9% to 19.4%) and metastases (from 12.5% to 22.4%) had histological examination, and use of endoscopy increased to approximately 10%. Relative survival after diagnosis of pancreatic cancer remains very low. However, in recent years, a modest improvement in short-term survival has been noted, with 1-year survival rates of 18% and 16% for males and females, respectively. The incidence and mortality for pancreatic cancer remain largely unchanged, with few 5-year survivors. Improved short-term survival may reflect more aggressive use of surgery and chemotherapy. Further elucidation of risk factors in pancreatic cancer is needed to enable effective prevention, early detection and improved treatment strategies.
    Scandinavian Journal of Gastroenterology 11/2009; 45(1):82-92. DOI:10.3109/00365520903358899 · 2.36 Impact Factor
  • Burns: journal of the International Society for Burn Injuries 04/2010; 36(6):e111-4. DOI:10.1016/j.burns.2009.12.004 · 1.88 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background / Purpose: Pancreatic adenocarcinoma initially presenting with a large osteoblastic lesion of the pelvis is uncommon. Two patients presented with large boney masses found to be metastatic pancreatic adenocarcinoma. Main conclusion: The important aspect of this poster lies in the necessity to biopsy suspicious lesions in order to make an accurate diagnosis to assure that appropriate treatment is obtained.
    Journal of Clinical Oncology 10/2010; 28(29):e545-9. DOI:10.1200/JCO.2010.28.6153 · 18.43 Impact Factor
Show more